Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Akero Therapeutics Inc (AKRO)

Akero Therapeutics Inc (AKRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference GlobeNewswire - Tue Jun 3, 6:00AM CDT

AKRO : 54.90 (-0.90%)
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference GlobeNewswire - Wed May 28, 6:00AM CDT

AKRO : 54.90 (-0.90%)
Author
Best Biotech Stocks to Buy in 2025 MarketBeat - Tue May 13, 7:10AM CDT

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

VRTX : 448.40 (+1.45%)
AKRO : 54.90 (-0.90%)
REGN : 513.58 (+0.93%)
XBI : 82.66 (+0.68%)
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Mon May 12, 6:00AM CDT

AKRO : 54.90 (-0.90%)
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 GlobeNewswire - Sat May 10, 9:00AM CDT

AKRO : 54.90 (-0.90%)
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine GlobeNewswire - Fri May 9, 6:11AM CDT

AKRO : 54.90 (-0.90%)
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 GlobeNewswire - Fri May 9, 5:15AM CDT

AKRO : 54.90 (-0.90%)
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference GlobeNewswire - Wed May 7, 3:05PM CDT

AKRO : 54.90 (-0.90%)
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 GlobeNewswire - Wed Apr 30, 6:00AM CDT

AKRO : 54.90 (-0.90%)
Author
3 Mid-Caps Worth Watching Closely in March  MarketBeat - Fri Feb 28, 6:55AM CST

Unlike their mega-cap counterparts, which tend to grind, mid-caps can soar or crash within days, driven by headlines and pure speculation.

AKRO : 54.90 (-0.90%)
HEES : 94.64 (-0.63%)
OKLO : 62.02 (-1.19%)
HRI : 111.68 (+0.24%)

Barchart Exclusives

3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio Barchart - 1 hour ago
These funds are reshaping income investing in 2025. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot